<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01114711</url>
  </required_header>
  <id_info>
    <org_study_id>2009-P-001452</org_study_id>
    <secondary_id>400479</secondary_id>
    <nct_id>NCT01114711</nct_id>
  </id_info>
  <brief_title>Frovatriptan and Menstrual Migraine</brief_title>
  <acronym>FROVA</acronym>
  <official_title>Mapping CNS Changes to Frovatriptan Administration in Acute Treatment of Prodrome or Preventative Treatment of Menstrual Migraine (MM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mclean Hospital</source>
  <brief_summary>
    <textblock>
      We are looking for women who suffer from menstrual migraine to participate in a 2-visit&#xD;
      migraine brain imaging research study. Our goal is to see how the menstrual migraine brain's&#xD;
      pain pathways function when the migraineur has been taking Frovatriptan. During the screening&#xD;
      visit (Visit 1) participants will sign the informed consent form, complete questionnaires,&#xD;
      meet with the study physician, and have QST (quantitative sensory testing: to determine your&#xD;
      pain thresholds for a heat stimulus) performed. For Visit 2's MRI scan, subjects will be&#xD;
      asked to lie very still while the scan is occurring. In some parts, they will not have to do&#xD;
      anything, while in others they will be asked to rate pain and unpleasantness for brush and&#xD;
      thermal stimuli. Participants are compensated for both visits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    A sister study using Frova at a 10 mg dose had adverse effects.&#xD;
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">24</enrollment>
  <condition>Frovatriptan</condition>
  <condition>Menstrual Migraine</condition>
  <arm_group>
    <arm_group_label>Frovatriptan</arm_group_label>
    <description>All subjects will be taking Frovatriptan tablets within 48 hours prior to the scan session (Visit 2).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Females who suffer from menstrual migraine who are over the age of 18 and have not yet&#xD;
        experienced menopause are the study population.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Regular Menstrual Phase&#xD;
&#xD;
          -  Menstrual Migraine&#xD;
&#xD;
          -  No significant medical history (Significant medical history of such as seizure&#xD;
             disorder, diabetes, alcoholism, cardiac disease including coronary artery disease,&#xD;
             psychiatric problems; drug addiction, respiratory problems, liver disease, etc.)&#xD;
&#xD;
          -  No significant medication history, except for migraine&#xD;
&#xD;
          -  All patients will be currently taking or have previously taken triptan medications for&#xD;
             migraine&#xD;
&#xD;
          -  Weight, &lt;285 pounds&#xD;
&#xD;
          -  Not claustrophobic&#xD;
&#xD;
          -  No contraindication to taking triptans&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18&#xD;
&#xD;
          -  Significant medical problems (aside from pain before, during and after migraine&#xD;
             episodes)&#xD;
&#xD;
          -  Positive drug of abuse screen (excluding medications currently prescribed for their&#xD;
             clinical condition, e.g. opioids, benzodiazepines, etc.)&#xD;
&#xD;
          -  Positive alcohol screen&#xD;
&#xD;
          -  Women taking oral contraceptives&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  History of dermatological hypersensitivity in the facial area&#xD;
&#xD;
          -  Positive history of cardiac problems/ abnormalities seen in EKG at initial screening&#xD;
             visit&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Sensory loss detected on Quantitative Sensory Testing at screening&#xD;
&#xD;
          -  Significant alcohol history (ingestion of 5 or more glasses (&gt; 40 oz) of alcohol per&#xD;
             week)&#xD;
&#xD;
          -  Metal implants of any type (including dental bridges, crowns, retainers, orthodontic&#xD;
             devices e.g. braces, etc.)&#xD;
&#xD;
          -  Tattoos containing metallic ink on the neck, shoulders, upper arm and head (which&#xD;
             could become heated up in the scanner, and potentially cause blistering or burning)&#xD;
&#xD;
          -  Cardiac pacemakers&#xD;
&#xD;
          -  Aneurysm clips and other vascular stents, filters, clips or other devices&#xD;
&#xD;
          -  Prosthetic heart valves&#xD;
&#xD;
          -  Other prostheses&#xD;
&#xD;
          -  Neuro-stimulator devices&#xD;
&#xD;
          -  Implanted infusion pumps&#xD;
&#xD;
          -  Cochlear (ear) implants&#xD;
&#xD;
          -  Ocular (eye) implants or known metal fragments in eyes&#xD;
&#xD;
          -  Exposure to shrapnel or metal filings (sheet metal workers, welders, and others)&#xD;
&#xD;
          -  Other metallic surgical hardware in vital areas&#xD;
&#xD;
          -  Use of any of the following medications:&#xD;
&#xD;
          -  Propanolol/ Inderol&#xD;
&#xD;
          -  SSRI's: citalopram/ Celexa, Lepraxo, paroxetine/ Paxil, fluoxetine/ Prozac, Sarafem,&#xD;
             Symbyax, sertraline/ Zoloft, Fluvoxamine/ Luvox&#xD;
&#xD;
          -  SNRI's: duloxetine/ Cymbalta, venlafaxine/ Effexor&#xD;
&#xD;
          -  triptans: sumatriptan/ Imitrex, naratriptan/ Amerge, zolmitriptan/ Zomig, rizatriptan/&#xD;
             Maxalt, eletriptan/ Relpax, almotriptan/ Axert&#xD;
&#xD;
          -  ergotamine type medicines: Bellergal, Cafergot, Ergomar, Wiraine, Migranal/ DHE45,&#xD;
             Sansert&#xD;
&#xD;
          -  ketoconazole (Nizoral, Fungoral)&#xD;
&#xD;
          -  itraconazole (Sporanox)&#xD;
&#xD;
          -  ritonavir (Norvir)&#xD;
&#xD;
          -  erythromycin (Erythrocin)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Borsook, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neuroimaging Center, McLean Hospital</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 29, 2010</study_first_submitted>
  <study_first_submitted_qc>April 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2010</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>David Borsook, MD, PhD</investigator_full_name>
    <investigator_title>Director, Pain and Analgesia Imaging Group</investigator_title>
  </responsible_party>
  <keyword>Menstrual Migraine</keyword>
  <keyword>Frova</keyword>
  <keyword>Imaging</keyword>
  <keyword>fMRI</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Premenstrual Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

